ClinicaliQ Trial Snapshot
- A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma — Recruiting • Phase I • Cardiology / Cardiovascular • NCT06988488.
- What is being tested: A phase 1b/2 dose-escalation and expansion study evaluating mezigdomide (cereblon E3 ligase modulator) combined with elranatamab (GPRC5D-targeted bispecific antibody) to establish the recommended phase 2 dose and assess safety and preliminary efficacy in relapsed/refractory multiple myeloma.
- Patient eligibility overview: The trial includes patients with relapsed and/or refractory multiple myeloma who have received prior treatment; specific eligibility criteria (prior therapy lines, performance status, organ function) determine individual suitability for enrolment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Eligibility Snapshot
- : * Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2). * Measurable MM by local laboratory. * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1. * Adherence to contraception requirements.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.